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A B S T R A C T
Background and objectives: We examined a mechanism that may coordinate trade-offs between repro-
duction and immune response in healthy women, namely, changes in inflammation across the ovarian
cycle.
Methodology: We investigated C-reactive protein (CRP), an inflammation marker, across two consecu-
tive ovarian cycles in 61 Bolivian women. Participants provided saliva samples every other day, and dried
blood spots on 5–6 days spread across weeks 2–3 of each cycle. Cycles were characterized as ovulatory/
anovulatory based on profiles of reproductive hormones. Participants also reported whether they were
sexually partnered with a male or sexually abstinent during the study.
Results: High early-cycle, but not late-cycle, CRP was associated with anovulation. High inflammation at
the end of one cycle was not associated with anovulation in the subsequent cycle. Among ovulatory
cycles, women with sexual partners had significantly lower CRP at midcycle, and higher CRP at follicular
and luteal phases; in contrast, sexually abstinent women had little cycle-related change in CRP. In
anovulatory cycles, partnership had no effect on CRP. CRP varied significantly with socioeconomic
status (higher in better-off than in poorer women).
Conclusions and implications: These findings suggest that the cycle-specific effect of inflammation on
ovarian function may be a flexible, adaptive mechanism for managing trade-offs between reproduction
and immunity. Sociosexual behavior may moderate changes in inflammation across the ovarian cycle,
suggesting that these shifts represent evolved mechanisms to manage the trade-offs between repro-
duction and immunity. Clinically, these findings support considering both menstrual cycle phase and
sexual activity in evaluations of pre-menopausal women’s CRP concentrations.
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BACKGROUND AND OBJECTIVES
Inflammation increasingly has been regarded as a
health risk, in part due to its association with a
variety of chronic conditions including metabolic
syndrome, pain disorders, cardiovascular disease
(CVD) and depression [1–6]. Such evidence has
tended to obscure the long-recognized adaptive
function of inflammation to signal physical chal-
lenges (infection or damage) and coordinate im-
mune response with other physiologic functions
including reproduction [7–13].
Evolutionary theory argues that because the
immune system and reproduction each require sub-
stantial resources (e.g. energy, micronutrients), an
organism must typically trade off finite resource
allocations between these demands; that is, concur-
rent maximum investments in reproduction and im-
mune defenses are unlikely [11, 14–16] with some
possible exceptions such as following acute expos-
ure to cortisol [17]. In addition to competition for
resources, the inherent non-specificity of inflamma-
tion makes it a potent immune response to innumer-
able foreign cells including, potentially, sperm or a
conceptus. Thus, natural selection may favor a tran-
sient dampening of maternal immune defense to
bodily threats so as to increase the chances for suc-
cessful reproduction. This dampening, however,
may come at significant health costs to women
(e.g. infertility, autoimmune diseases, sexually
transmitted infections) [18–23].
Such trade-offs have long been studied both the-
oretically and empirically. In On the Origin of Species,
Darwin wrote (citing Goethe), ‘In order to spend on
one side, nature is forced to economize on the other
side’ [24]. This simple calculus is at the heart of var-
ied allocation compromises (for assessments of im-
mune-reproduction trade-offs in humans, see e.g.
McDade [25], Muehlenbein and Bribiescas [26],
Abrams and Miller [13] and Clancy [9]; a few ex-
amples from the vast literature on non-human ani-
mals are Lochmiller and Deerenberg [10], Sheldon
and Verhulst [12], Norris and Evans [27] and Demas
et al. [28]).
We tested three hypotheses grounded in evolu-
tionary theory regarding the trade-offs between in-
flammation, sexual activity and ovulation in a
sample of healthy Bolivian women not using hormo-
nal contraception. To track changes in inflammation
during the ovarian cycle, we measured C-reactive
protein (CRP), an acute-phase protein produced by
the liver in response to signals from immune agents
such as macrophages [29]. Low circulating concen-
trations of CRP reflect a broad array of processes
related to ongoing baseline somatic maintenance,
but rise abruptly within about 2 h of an acute insult.
Given its relatively short half-life (19 h), CRP concen-
trations reflect the rate of synthesis, driven directly
by innate inflammatory processes [30]. These fea-
tures make CRP a particularly valuable biomarker
of inflammation and, due to its increasingly com-
mon use in clinical settings to predict risk of condi-
tions such as CVD [31–33], its use in our study
affords the opportunity to evaluate the clinical sig-
nificance of our findings.
Hypothesis 1: High CRP during the follicular phase
is associated with an increased risk of anovulation. We
predict that women experiencing high inflammation
(as indexed by high CRP) will be less likely to ovulate,
instead favoring physiologic processes related to in-
flammation such as defense or healing. Anovulation
is an unambiguous signal of terminated effort in the
current reproductive opportunity. Such temporary
suspension of reproductive investment may be evo-
lutionarily adaptive [34–40]. As well as diverting the
resources necessary to mount an adequate immune
response (including inflammation), a conception
during periods of high inflammation might have a
substantially reduced chance of developing into a
viable offspring because the embryo may be harmed
by the activated maternal immune system, diversion
of energetic resources to the immune system and,
potentially, the presence of pathogens [41, 42].
Natural selection would, therefore, favor not
conceiving in a cycle in which heightened immune
defenses are needed.
Hypothesis 2: The effect of high inflammation on
ovulation is cycle-specific. Because natural selection
over a lifetime favors reproduction, acute inflamma-
tion generally may be expected to have short-term
rather than prolonged effects on ovarian functioning
in adulthood. Specifically, we predict that ovarian ac-
tivity in each cycle responds independently to
transient inflammation, that is, inflammation
during one cycle would not predict anovulation in
the next.
Such acute responsivity would allow the body to
opt for anovulation flexibly by reevaluating and re-
sponding to immune status at each cycle. Evidence
suggests that the ovarian system uses short-term
cycle-specific strategies (as well as other strategies,
e.g. across sequential cycles [43]) to coordinate with
other physiological systems (e.g. under stressful
conditions, cross-talk between the HPA- and
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HPG-axes coordinates suppression of reproductive
investment [44, 45]). Similarly, the endocrine and
immune systems engage in cross-talk during preg-
nancy to evaluate physical and psychosocial stres-
sors to determine ongoing investment in the
pregnancy versus premature delivery [46–48].
Hypothesis 3: Patterns of inflammation are
moderated by sexual partnership status such that, rela-
tive to unpartnered women, sexually active women will
have higher inflammation overall, but exhibit a de-
crease in inflammation corresponding to the occurrence
and timing of ovulation. Sexually active women are at
a greater risk than abstinent women for sexually
transmitted infections and/or genital irritation.
Therefore, we predict that sexually partnered women
will exhibit relatively higher CRP concentrations dur-
ing those portions of the cycle when the probability
of conception is lower (i.e. the early to mid-follicular
and mid- to late luteal phases). We also predict that
in healthy sexually active females, the immune sys-
tem will temporarily down-regulate non-specific de-
fenses (such as inflammation) at ovulation to
mitigate disruption of conception. Indeed, two very
recent US-based studies have found that some im-
mune markers differ significantly in sexually active
versus abstinent women [49–51]. However, to date
there are few data regarding the interaction of sex-
ual activity, cycle ovulation status and inflammation
in healthy premenopausal women. This is a signifi-
cant gap in our knowledge, as there is reason to
expect that sexual activity may have different ef-
fects on immune response at fecund points of ovu-
latory cycles (i.e. around ovulation) than
during other times, or in comparison to anovulatory
cycles.
We selected this Bolivian population for testing
these three hypotheses because it affords an oppor-
tunity to understand both cycle-associated variation
in CRP and reproductive-immune trade-offs in
women living in very demanding conditions [52, 53].
The overwhelming bulk of research on CRP has been
conducted in US and European populations. To com-
plement this work, several researchers have called for
studies in a broader range of living conditions, health
care practices and pathogen burdens [8, 25, 54–58].
Dissimilar habitats, particularly when experienced
early in life, are thought to differentially influence
the trajectory of immune responses and the
associated physiological trade-offs [8, 25, 54].
Groundbreaking work on variation in CRP in both
adults and children has been conducted in a handful
of non-Western (i.e. neither European or Euro-
American [59]) populations in Siberia [60, 61],
Ecuadorian [62, 63] and Bolivian [57, 64–67]
Amazonia, and the Philippines [68–72]. These studies
addressed questions regarding the prevalence of
chronic inflammation, risks for cardiovascular and
other chronic diseases (particularly under conditions
of endemic infectious disease), aging, depression,
links between early life conditions and later life health,
and trade-offs between immune functioning and
growth.
Despite these advances, however, variation in im-
mune biomarkers during the ovarian cycle, or in rela-
tion to women’s reproductive functioning more
generally, has been relatively unexamined in non-
Western populations. One exception is a study from
the Philippines that reported significantly higher CRP
in late gestation compared with nulliparous women
but no difference in CRP with respect to breastfeeding
status [56]. The authors suggested that during human
evolutionary history, adult females may have spent
more time in a pro-inflammatory state compared with
other great apes experiencing fewer pregnancies and
longer lactation durations, but they also cautioned
that the health or energetic costs of such a pro-inflam-
matory shift are uncertain.
Studies on whether CRP varies in concert with cyc-
lical changes in one or another reproductive hor-
mone have been conducted in Austria [73],
Switzerland [74, 75], Italy [76], Poland [55] and the
USA [77, 78]. For the most part, this work has
evaluated proximate mechanisms (in particular,
the hypothesized pro- or anti-inflammatory effects
of endogenous reproductive hormones) that may
cause serum CRP to rise or fall. In the one study to
address these questions using a urinary CRP bio-
marker, Clancy et al. [55] adopted an evolutionary
approach, predicting that higher CRP would be
correlated with lower progesterone and estradiol in
a sample of rural Polish women. Most of these
studies also considered whether serum CRP meas-
urements should be adjusted for menstrual cycle
phase.
Collectively, the results from these studies (con-
sidered further in the Conclusions and Implications
section) are quite mixed (and even contradictory for
a given sample), perhaps due to differences in study
design and analytical approaches (e.g. inattention to
cycle ovulation status). In particular, the focus on
absolute concentrations of reproductive steroids
may need to be reconsidered because these hor-
mones are highly variable and because absolute
306 | Lorenz et al. Evolution, Medicine, and Public Health
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reproductive hormone concentrations are an am-
biguous signal of reproductive investment.
There is now substantial evidence attesting to the
considerable natural variation across cycles (within
an individual), women (within a population) and
populations in concentrations of ovarian steroids
during normal spontaneous menstrual cycles
[38, 79]. It has also been demonstrated that women
with progesterone concentrations lower than some
population average, and populations with such con-
centrations lower than those observed in US women,
are not necessarily subfecund [80, 81]. In the face of
such variability, one may fail to find a correlation
between CRP and some steroid concentration if
the typically small samples have insufficient statis-
tical power (notably, several of the studies on CRP–
hormone associations specifically reported a con-
cern with sample size). Even given large sample
sizes, CRP–hormone associations may vary across
women because of individual differences in the inter-
actions of baseline CRP and hormone concentra-
tions (a subject for much needed research).
A key implication of such marked hormonal vari-
ability for studies of evolved immunity-reproduction
trade-offs is that lower steroid hormone concentra-
tions need not necessarily indicate a reduction in
reproductive effort. Although ecological stressors
may be accompanied by a reduction in ovarian ster-
oids that suggest reduced (but still not zero) invest-
ment in reproduction, it does not follow that normal
inter-cycle variability in hormone concentrations is
necessarily a reflection of varying reproductive
effort. In contrast, anovulation is an unambiguous
signal of terminated effort in the current reproduct-
ive opportunity. For this reason, we have chosen to
evaluate hypothesized immune-reproduction trade-
offs using the ovulatory status of a cycle as the
marker of reproductive investment.
Sexual partnership is likely to be a key factor
moderating immune-reproduction trade-offs in
women that has yet to be considered in studies of
cycle-associated CRP variation. Beginning with
Metcalf’s ground breaking work on ovulation rates
in New Zealand women, several studies have shown
that sexual partnership is associated with higher
ovulation rates, particularly when women are living
apart from close relatives [82–85]. Furthermore, very
recent work has demonstrated that some immune
parameters differ significantly in sexually active ver-
sus abstinent US women [49–51]. These findings all
point to a significant role for the social and sexual
environments as predictors of ovarian and immune
functioning.
As previously noted, one can reasonably expect
natural selection to favor a transient dampening of
maternal immune defenses so as to increase
the chances for successful reproduction. In add-
ition, one can also reasonably expect that natural
selection would differentially favor such dampen-
ing, including the accompanying increased health
risks, in those women who are actually at risk for
conception, i.e. in sexually active women as
opposed to sexually abstinent women.
Although we draw widely on a preceding body of
evolutionary theory and evidence, to the best of our
knowledge, the specific hypotheses we propose to
test have not been previously evaluated. In addition,
our study of hypothesized immune-reproduction
trade-offs in a non-Western population with higher
pathogen load than is typical of wealthier countries
is itself a test of whether such cycle-associated vari-
ation in inflammation is likely to be an evolved and
adaptive mechanism or a newer phenomenon re-
flective of some aspect of modern life.
Clinical implications
In the concluding section, we discuss the signifi-
cance of our findings for clinical practice. Because
serum CRP is a commonly used biomarker for as-
sessing the risk of CVD, and both some prior work
and the hypotheses we tested suggest that CRP is
likely to vary over the ovarian cycle, we evaluate the
consequences of such changes for assessing CVD
risk in nominally healthy adult women. In a recent
study of US women, Schisterman et al. [86] found
that, due to natural variation in CRP across the men-
strual cycle, the same women were twice as likely to
be diagnosed as high CVD risk during menses than
at any other point in the cycle, indicating that
failure to account for timing within the ovarian
cycle likely leads to clinical misinterpretation
of inflammation biomarkers in premenopausal
women.
METHODS
The data presented here were collected as part of a
study of the determinants and consequences of vari-
ation in reproductive functioning in urban-dwelling
Bolivian women [52, 87]. Participants were recruited
and samples were collected from May through mid-
August 1995. All samples were treated identically
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during sampling, storage, shipping and analysis (de-
tails presented further below). Saliva assays were
performed during 1996, and assays of dried blood
spots (DBS) assays were performed during
November 2004 through February 2005.
Participants
Sixty-one women (age 23–35 years, mean = 28.13
years) were recruited from La Paz, the capital of
Bolivia, and Pasenkeri, a poor community on the
outskirts of La Paz. Participants were recruited via
announcements (to meetings at the Pasenkeri com-
munity center and to classes at the university) and
word of mouth. Inclusion criteria comprised having
regular ovarian cycles between 25 and 35 days inclu-
sive, stable weight (no more than ±2 kg in the last 6
months) and continuous residence at high altitude
(>3500 m) since early childhood. Exclusion criteria
included use of prescription medications (including
hormonal contraceptives) during the previous 6
months, pregnancy or lactation during the previous
6 months, or any known current or previous sexually
transmitted infection or reproductive disorder.
Screening interviews and informed consent proced-
ures were conducted in the participant’s native lan-
guage (Spanish or Aymara). All procedures were
approved by the Institutional Review Board at the
University of California at Riverside.
Saliva and blood spot collections
For two complete consecutive cycles, serial 5 ml
saliva samples were collected every other day (ei-
ther Monday–Wednesday–Friday or Tuesday–
Thursday–Saturday; the same weekly schedule
was maintained throughout the study for a given
participant) according to an established protocol
[88]. During the second and third week of each
cycle, beginning in the mid-follicular phase (i.e. be-
ginning on cycle Day 6 or 7 or 8) and continuing
through the presumed mid-luteal phase (i.e. de-
pending on the start day, ending on cycle Day 21
or 22 or 23 or 24), blood spot samples were col-
lected concurrently with saliva samples on 5–6 oc-
casions. Per our published procedure, after
collection, blood spot sample papers were dried
for 3–4 h at ambient temperature, then placed in
a sealed bag with a desiccant packet and stored in a
2C laboratory refrigerator until transported with
cold packs, within 6 weeks of collection, to Emory
University for processing [89]. Upon receipt, DBS
were stored frozen at28C until assayed. All saliva
samples were treated with sodium azide (an anti-
microbial preservative) and stored at cool ambient
temperature (averaging 15C) until shipped to
the USA, where they were stored frozen at 28C
until assayed [52].
CRP assay
DBS were assayed for CRP using a high-sensitivity
europium-labeled biotin–strepavidin system that
improved on a previously published method [90]
(additional details are provided in Supplementary
Data, permanently archived at http://hdl.handle.
net/2022/20415 29 November 2015, date last
accessed). Assay minimum detectable dose was
0.010 mg/l; coefficients of variation (CV) were
low: intra-assay (1.2–2.0%) and inter-assay (10.9–
14.9%; see archived Supplementary Data for all
values). As reported elsewhere, a validation study
using matched serum and DBS samples was per-
formed and found a close linear correlation such
that serum equivalents can be computed from DBS
values using this algorithm: high-sensitivity CRP
mg/l = 1.38 * (DBS CRP mg/l)  0.97 [91].
A total of 639 DBS from 61 women collected
across two cycles were assayed for CRP, of which
65 measurements were excluded from further ana-
lyses (9 from one participant who conceived during
her first cycle; and 56 from 10 cycles across 10
women that could not be characterized as either
ovulatory or anovulatory (see section below on
ascribing ovulation)). Of the remaining 574 measure-
ments, 23 were >4 mg/l (indicating acute inflamma-
tory response). These values were retained; however,
due to these few very high values, the raw CRP data
were significantly right-skewed. Therefore, we used
the natural log of CRP in all analyses. It should be
noted that in no participant was CRP >4 mg/l for
longer than three consecutive samples (at most, 6
days total over two cycles); that is, observed CRP ele-
vations were acute, not chronic. Summary character-
istics of CRP are presented in Table 1. Note that
average CRP values are taken across repeated meas-
ures which are not statistically independent; thus, the
F and P values for CRP contrasts in Table 1 are pre-
sented for general interpretation only.
Hormone assays and ascribing ovulation
DBS for one of a woman’s two cycles (selected arbi-
trarily, without regard to CRP concentrations or any
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other cycle characteristics) were assayed for proges-
terone (P4), estradiol (E2), luteinizing hormone
(LH) and follicle stimulating hormone (FSH) using
previously published methods [89]. CVs were accept-
able (intra-assay range, 2.5–19.8%, inter-assay
range, 6.1–34.8%; assay performance details are in
Supplementary Data, archived at http://hdl.handle.
net/2022/20415). Saliva samples were assayed for
unbound (free) P4, the results of which have been
previously published [52].
We used multiple hormonal criteria to ascribe ovu-
lation to each cycle. A cycle was characterized as ‘ovu-
latory’ if mean-peak-salivary-P4>110 pmol/l [52]. For
cycles in which DBS were assayed for hormones, as-
sessment of ovulatory status was supplemented by
the following criteria: a clear mid-cycle surge of LH
and FSH, an accompanying relative peak of E2 at mid-
cycle and/or a late-cycle rise in serum P4. Seventy-
three cycles were characterized as ovulatory (Cycle
1, N = 36; Cycle 2, N = 37). Cycles were characterized
as ‘anomalous’ and dropped from further analyses
(Cycle 1, N = 7; Cycle 2, N = 3) if the salivary and
serum P4 criteria were not in agreement, or if unusual
features were present (e.g. an apparent late-cycle peak
in LH). Cycles lacking any manifest features of ovula-
tion were characterized as ‘anovulatory’ (Cycle 1,
N = 17; Cycle 2, N = 17). Ascribed ovulation status
was independent of whether or not DBS hormonal
data were used (Fisher’s Exact Test, P = 0.45). For
cycles categorized as ovulatory, the day of ovulation
was determined from the LH/FSH peak and/or the
post-ovulatory rise in salivary P4.
Other measures
At the initial interview, participants reported their
age and current sexual partnership status (with
[n = 31] or without [n = 29] a male partner). Given
the patterns of contraception use and pregnancy
within this sample and within this culture, we can
conclude that the partnered women were regularly
sexually active [52]. Unpartnered women reported
that they did not engage in sexual activity during
the study period (and based on the hormonal data,
no conceptions occurred during the study period in
this subsample); thus, consistent with this culture’s
mores, it is likely that unpartnered women were
rarely, if ever, sexually active. Of note, ovulation
was not associated with partnership status in this
sample (2(1) = 0.80,P = 0.41). Participants were
also measured for height and weight; from this, body
mass index (BMI) was calculated as weight/height2.
Partnered and unpartnered women did not differ in
the protocols followed, the number of samples col-
lected per participant, or in the collection, handling
and assaying of their samples.
Table 1. Descriptive statistics for study sample
Partnered
women (N = 31)
Unpartnered
women (N = 29)
Total (N = 60) Contrast
partnered
versus
unpartnered
women
Contrast
ovulatory
versus
anovulatory
cycles
Ovulatory
cycle
Anovulatory
cycle
Ovulatory
cycle
Anovulatory
cycle
M SD M SD M SD M SD M SD F P F P
Age 31.00 3.23 26.84 3.19 26.79 3.38 27.13 4.21 28.19 3.95 6.60 0.01
BMI 24.33 3.47 25.39 2.68 22.86 2.73 25.79 2.47 24.18 3.16 1.88 0.18
Cycle length 26.97 3.05 27.05 1.86 28.26 2.84 28.47 4.93 27.66 3.22 4.60a 0.03a 0.00 0.98
Forward
cycle day of
ovulation
15.09 2.89 16.03 2.77 15.59 2.88 2.02a 0.16a
CRP (mg/l),
average
across cycle
0.82 1.48 0.92 1.18 0.72 1.24 1.17 1.77 0.85 1.40 0.00a 0.99a 4.56a 0.03a
aNote that repeated measures are not statistically independent, therefore these F and P values are not useful for statistical inference.
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Statistical analyses
The archived data used in the following analyses
are freely and permanently available at http://hdl.
handle.net/2022/20420. All statistics were con-
ducted with SPSS version 22. Because CRP is posi-
tively correlated with age and BMI in at least some
populations [92], all our fitted models included these
potential confounders.
To test our first hypothesis (CRP is higher during
the follicular phase in anovulatory cycles), we fitted a
repeated measures mixed model (outcome variable
was lnCRP) with random intercepts by participant
(to adjust for individual differences in baseline
CRP), controlling for age (centered at 28, i.e. near
mean age), BMI (centered at 24, i.e. near mean BMI)
and socioeconomic status (SES, dichotomized as
poorer or better-off, see Ref. [52] for details). As the
dependent variable (lnCRP) was continuous, we
assumed a Gaussian distribution. Because anovula-
tory cycles cannot be evaluated with respect to the
day of ovulation, the repeated measures variables
were cycle and reverse day (i.e. day relative to first
day of subsequent cycle). We defined a phase vari-
able to allow for possible differences by cycle phase,
coded as 0 if reverse day <14 (i.e. early cycle (ap-
proximates follicular phase)) or 1 if reverse
day14 (i.e. late cycle (approximates luteal
phase in ovulatory cycles)). We parameterized time
dependence with two terms: the interaction of phase
with ovulation status (ovulatory/anovulatory)
and the interaction of phase with ovulation status
with (reverse day + 14)2. We used an autoregressive
model of the repeated measures covariance;
this model type assumes that the best predictors
of each repeated measure are the measures
closest to it in time (e.g. the best predictors of CRP
at Day 10 are the measures at Day 8 and
Day 12).
To test our second hypothesis (the effect of high
inflammation on ovulation is cycle-specific), we
coded a participant’s first cycle as exhibiting high
inflammation late in the cycle if there was a high
CRP value in Day 14 or later. We tested two poten-
tial cutoffs: untransformed CRP>2.02 mg/l, cor-
responding to the mean (M = 0.72 mg/l), plus one
standard deviation (SD = 1.31 mg/l), across all
Cycle 1 luteal phase samples; and untransformed
CRP>3.0 mg/l, the cutoff most often used in
Western populations (as recommended by the
American Heart Association (AHA) [32]). Within
Cycle 1, 15% of the cycles had samples over
the>2.02 mg/l cutoff and characterized as ‘high
late-cycle inflammation’, and 5% of the cycles had
at least one sample that met criteria
under the>3.0 mg/l cutoff. To examine whether
anovulation in the subsequent cycle was independ-
ent of late-cycle high inflammation in the first
cycle, we conducted Fisher’s Exact Test for
independence.
To test our third hypothesis (patterns of inflam-
mation are moderated by sexual partnership status),
we fitted a pair of repeated measures mixed models,
each with lnCRP as the outcome variable and ran-
dom intercepts by participant (similar to our test of
Hypothesis 1). We controlled for centered age, cen-
tered BMI and SES. We used an autoregressive
model of the repeated measures covariance and
assumed a Gaussian distribution. For the model
fitted to those data from ovulatory cycles, the re-
peated measures variables were cycle and day-rela-
tive-to-ovulation. In this model, phase was coded as
0 if day-relative-to-ovulation< 0 (i.e. follicular) or 1 if
day-relative-to-ovulation0 (i.e. luteal). We
parameterized time dependence with two terms:
the interaction of phase with partner status
(partnered/no-partner) and the interaction of phase
with partner status with (day-relative-to-ovulation)2.
For the model fitted to those data from anovulatory
cycles, phase was coded relative to reverse day
(as in the test of Hypothesis 1) and the repeated
measures variables were cycle and reverse day (also
as in the test of Hypothesis 1). We parameterized
time dependence with two terms: the interaction
of phase with partner status and the inter-
action of phase with partner status with (reverse
day + 14)2.
RESULTS
Hypothesis 1: High CRP during the follicular
phase is associated with an increased risk of
anovulation
Parameters for this model are given in Table 2 and
plotted in Fig. 1. CRP concentrations in the early
phase of anovulatory cycles (dashed lines) were sig-
nificantly higher (P = 0.034) than those of ovulatory
cycles (solid lines). In contrast, CRP did not differ
between ovulatory and anovulatory cycles during
late cycle. These findings support Hypothesis 1. An
additional finding was that serum equivalent CRP
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concentrations were significantly higher (P = 0.034)
in better-off women (blue lines) than in poorer
women (orange lines).
Hypothesis 2: The effect of inflammation on
ovulation is cycle-specific
High inflammation in the latter half of a woman’s
first cycle was not significantly associated with
anovulation in the subsequent cycle, using either
the sample-specific cutoff of CRP>2.02 mg/l
(Fisher’s Exact Test, P = 0.47), or the Western-
population cutoff of CRP>3.0 mg/l (Fisher’s Exact
Test, P = 0.66). Thus, there was evidence for
Hypothesis 2.
Hypothesis 3: Patterns of inflammation are
moderated by partnership status such that,
relative to unpartnered women, sexually active
women will have higher inflammation and a
decrease in inflammation corresponding to the
occurrence and timing of ovulation
The parameters for these models are presented in
Tables 3 and 4 and plotted in Figs 2 (ovulatory
cycles) and 3 (anovulatory cycles). In ovulatory
cycles, during the early follicular and late luteal
phases, partnered women (solid curves) had signifi-
cantly higher CRP concentrations (P = 0.029 and
0.055, respectively) than unpartnered women
(dashed curves). (Although the curvatures of the
same-color solid lines in the follicular and luteal
Table 2. Hypothesis 1 model parameter estimates (outcome variable is lnCRP)
Fixed effects
95% CI for b
Parameter b SE t P Lower Upper
Intercept 1.474 0.221 6.681 <0.001 1.911 1.036
Agea 0.022 0.031 0.732 0.467 0.038 0.081
BMIa 0.197 0.041 4.850 <0.001 0.116 0.279
SES
Better-off 0.563 0.260 2.169 0.034 0.044 1.083
Poorer (reference)
Ovulation * Phase
Anovulatory, Early phase 0.022 0.256 0.087 0.931 0.527 0.482
Anovulatory, Late phase 0.179 0.271 0.663 0.508 0.713 0.354
Ovulatory, Early phase 0.000 0.100 0.004 0.997 0.196 0.197
Ovulatory, Late phase (reference)
Ovulation * Phase * (Reverse day + 14)2
Anovulatory, Early phase 0.007 0.002 3.086 0.002 0.003 0.012
Anovulatory, Late phase 0.000 0.003 0.038 0.970 0.006 0.006
Ovulatory, Early phase 0.001 0.002 0.699 0.485 0.002 0.004
Ovulatory, Late phase 0.001 0.002 0.489 0.625 0.004 0.006
Random effects
Variance
Factor Estimate SE
Per-woman intercept 0.392 0.152
Repeated measures
Variance
Factor Estimate SE
First-order autoregressive diagonal 0.998 0.124
 0.866 0.019
aCentered.
Mediating reproductive-immune investments Lorenz et al. | 311
D
ow
nloaded from
 https://academ
ic.oup.com
/em
ph/article-abstract/2015/1/304/1798160 by guest on 03 June 2020
0.0
0.5
1.0
1.5
-25 -20 -15 -10 -5 0
Early-phase curvature:
anovulatory ≠ 0  (p=0.002)
anovulatory ≠ ovulatory (p=0.034)
C
R
P
 (
m
g/
dL
)
Reverse Day (relative to onset of next cycle)
Test of Hypothesis 1
better-off, anovulatory
better-off, ovulatory
poorer, anovulatory
poorer, ovulatory
0.01
0.1
1
10
-25 -20 -15 -10 -5 0
C
R
P
 (
m
g/
dL
)
Reverse Day (relative to onset of next cycle)
Test of Hypothesis 1 (log scale, CRP adjusted for Age & BMI)
model: better-off, anovulatory
model: better-off, ovulatory
model: poorer, anovulatory
model: poorer, ovulatory
data: better-off, anovulatory
data: better-off, ovulatory
data: poorer, anovulatory
data: poorer, ovulatory
A
B
Figure 1. Test of Hypothesis 1. (A) Fitted models. (B) Fitted models and CRP data (adjusted for age and BMI) plotted on a log scale; adjusted
CRP = exp(ln(observed CRP)  beta_age*(Centered_Age)  beta_BMI*(Centered_BMI)); data points are randomly dithered (slightly offset) on x-axis for ease
of viewing. CRP in the early phase of anovulatory cycles (dashed curves) is significantly higher (P = 0.034) than in ovulatory cycles (solid curves). In anovulatory
cycles, CRP is lower at mid-cycle than at the cycle’s beginning (fitted model curvature is significant at P = 0.002). In contrast to anovulatory cycles, CRP in ovulatory
cycles is more stable over time (fitted model curvature is not significantly different from 0). CRP is significantly higher (PSES = 0.034) in the cycles of better-off (blue
curves) than in those of poorer women (orange curves)
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phases are very similar, the respective statistical sig-
nificances differ because there are fewer data points
in the luteal phase.) Furthermore, CRP in partnered
women was significantly lower during the peri-ovu-
latory period than during the early follicular phase
(P = 0.005). In contrast, CRP in unpartnered women
changed little throughout the cycle (i.e. the curvature
of the model for unpartnered women was not signifi-
cantly different from 0); in other words, there was no
evidence of a peri-ovulatory decline in inflammation
as was observed in the partnered women. In an-
ovulatory cycles (Fig. 3), partnership status was
not associated with any changes in CRP concentra-
tions at any time during the cycle (i.e. the two blue
curves do not differ significantly nor do the two
orange curves). The results from these two models
support Hypothesis 3.
Note that none of the changes in lnCRP occurring
at the transition from follicular to luteal phase (i.e. at
ovulation in ovulatory cycles) or between early and
late phases (i.e. mid-cycle in anovulatory cycles) was
significant.
In addition, a comparison of the models fitted to
test hypotheses 1 and 3 (Figs 1–3) indicates that (for
a given SES and having controlled for BMI and age)
predicted CRP during early cycle was higher in an-
ovulatory cycles (regardless of partnership status)
than in ovulatory cycles from partnered women.
Indeed, the highest concentrations of CRP during
early cycle phase were associated with anovulatory
Table 3. Model parameters for Hypothesis 3a in ovulatory cycles only (outcome variable is lnCRP)
Fixed effects
95% CI for b
Parameter b SE t P Lower Upper
Intercept 1.563 0.266 5.881 <0.001 2.094 1.033
Agea 0.024 0.033 0.734 0.466 0.042 0.090
BMIa 0.205 0.041 5.052 <0.001 0.123 0.287
SES
Better-off 0.579 0.267 2.166 0.035 0.042 1.116
Poorer (reference)
Partnership * Phase
Unpartnered, Early phase 0.179 0.179 0.603 0.548 0.412 0.770
Unpartnered, Late phase 0.327 0.300 1.093 0.278 0.269 0.924
Partnered, Early phase 0.186 0.141 1.323 0.187 0.463 0.091
Partnered, Late phase (reference)
Partnership * Phase * (Day-wrt-ovulation)2
Unpartnered, Early phase 0.001 0.002 0.322 0.747 0.005 0.003
Unpartnered, Late phase 0.006 0.004 1.437 0.152 0.013 0.002
Partnered, Early phase 0.006 0.002 2.808 0.005 0.002 0.010
Partnered, Late phase 0.005 0.004 1.283 0.200 0.003 0.012
Random effects
Variance
Factor Estimate SE
Per-woman intercept 0.203 0.151
Repeated measures
Variance
Factor Estimate SE
First-order autoregressive diagonal 0.955 0.149
 0.856 0.026
aCentered.
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cycles and the lowest CRP concentrations were
associated with unpartnered ovulatory cycles.
Clinical implications: CVD risk
As CRP is used as a marker of risk for CVD, we
investigated the clinical significance of the patterns
of change in CRP reported above. We coded CRP
values as low, moderate or high CVD risk according
to the clinical interpretation guidelines recom-
mended by the AHA [32]. We then tested whether
there was a significant interaction between ovulation
status and cycle phase (early-cycle, or before Day 14,
vs late-cycle, or after Day 14) in predicting CVD risk
category using a 2-test for independence. There
was a significant interaction between ovulation and
cycle phase in predicting CVD risk category
(2(3) = 16.20, P = 0.01), such that at early cycle,
women with anovulatory cycles were significantly
less likely to fall into the low risk category
(2(3) = 15.44, P = 0.01). At late cycle, the difference
between ovulatory and anovulatory cycles in CVD
risk categories was marginally significant
(2(2) = 5.62, P = 0.06, Fig. 4).
CONCLUSIONS AND IMPLICATIONS
Inflammation is at the core of many critical and com-
plex clinical problems, from treating chronic pain to
diagnosing CVD risk to preventing obesity. Applying
an evolutionary perspective in research on natural
variations in inflammation, and trade-offs between
Table 4. Model parameters for Hypothesis 3b, in anovulatory cycles only (outcome variable is lnCRP)
Fixed effects
95% CI for b
Parameter b SE t P Lower Upper
Intercept 1.675 0.375 4.473 <0.001 2.434 0.917
Agea 0.021 0.064 0.336 0.740 0.109 0.151
BMIa 0.215 0.086 2.517 0.018 0.040 0.391
SES
Better-off 0.545 0.554 0.984 0.334 0.591 1.682
Poorer (reference)
Partnership * Phase
Unpartnered, Early phase 0.189 0.518 0.364 0.718 0.860 1.237
Unpartnered, Late phase 0.026 0.546 0.047 0.962 1.072 1.124
Partnered, Early phase 0.165 0.190 0.870 0.386 0.210 0.540
Partnered, Late phase (reference)
Partnership * Phase * (Reverse day + 14)2
Unpartnered, Early phase 0.009 0.003 3.331 0.001 0.003 0.014
Unpartnered, Late phase 0.001 0.004 0.142 0.887 0.009 0.008
Partnered, Early phase 0.008 0.005 1.579 0.116 0.002 0.017
Partnered, Late phase 0.002 0.004 0.430 0.668 0.007 0.010
Random effects
Variance
Factor Estimate SE
Per-woman intercept 0.563 0.454
Repeated measures
Variance
Factor Estimate SE
First-order autoregressive diagonal 1.217 0.470
 0.906 0.041
aCentered.
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Figure 2. Test of Hypothesis 3 in ovulatory cycles. (A) Fitted models. (B) Fitted models and CRP data (adjusted for age and BMI) plotted on a log scale; adjusted
CRP = exp(ln(observed CRP) beta_age*(Centered_Age) beta_BMI*(Centered_BMI)); data points are randomly dithered (slightly offset) on x-axis for ease of
viewing. Interaction between partnership status, SES and cycle day predicted CRP in ovulatory cycles. CRP is significantly higher during the early follicular and late
luteal phases (P = 0.029 and 0.055, respectively) in partnered (solid curves) than in unpartnered (dashed curves) women. In partnered cycles, CRP is lower around
ovulation than at the cycle’s beginning (fitted model curvature is significant at P = 0.005). In contrast to partnered women, CRP in the ovulatory cycles of
unpartnered women is more stable over time (fitted model curvature is not significantly different from 0). The small increases in CRP at ovulation are not
statistically significant in these models
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Figure 3. Test of Hypothesis 3 in anovulatory cycles. (A) Fitted models. (B) Fitted models and CRP data (adjusted for age and BMI) plotted on a log scale; adjusted
CRP = exp(ln(observed CRP) beta_age*(Centered_Age) beta_BMI*(Centered_BMI)); data points are randomly dithered (slightly offset) on x-axis for ease of
viewing. Partnership status does not significantly modify CRP in anovulatory cycles (i.e. within each SES [better-off = blue, poorer = orange], the solid [partnered]
curves do not differ significantly from the corresponding dashed [unpartnered] curves). In unpartnered women, CRP is significantly higher during the beginning of
the cycle than at mid-cycle (fitted model curvature is significant at P = 0.001); a similar cycle-day dependent change is seen in partnered women, but is not
statistically significant (P = 0.116). The small decreases in CRP observed at mid-cycle are not statistically significant in these models
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immunity and other key processes such as reproduc-
tion, can open up new avenues for addressing these
contemporary health challenges.
Novel contributions to literature
Researchers as early as Darwin have posited the ex-
istence of trade-offs [24] (Darwin’s thoughts on the
coordinated organization of an organism’s func-
tions as noted in On the Origin of Species, p. 11–12:
‘Hence, if man goes on selecting, and thus augment-
ing, any peculiarity, he will almost certainly uncon-
sciously modify other parts of the structure, owing
to the mysterious laws of the correlation of growth’,
and p. 178, ‘the whole organization is so tied to-
gether, during its growth and development, that
when slight variations in any one part occur and
are accumulated through natural selection, other
parts become modified’.). However, the mechan-
isms behind such trade-offs still are being actively
elucidated.
To the best of our knowledge, this is the first study
to document the association of CRP profiles with
ovulation status and sexual activity, and to do so in
a population with higher pathogen load and less ac-
cess to health care and other resources than are typ-
ically found in Western/industrialized nations. We
observed evidence of trade-offs between immune
status and reproductive functioning. Inflammation
early, but not late, in the cycle was associated with
anovulation. Ovulatory cycles were characterized by
a CRP nadir in the days surrounding ovulation (i.e.
mid-cycle); anovulatory cycles were not. High inflam-
mation late in one cycle did not predict anovulation
in the subsequent cycle, suggesting that inflamma-
tion-related ovarian suppression exhibits within-
cycle specificity. Finally, we found significant inter-
actions between cycle phase, sexual partnership and
inflammation: specifically, in ovulatory cycles the
observed mid-cycle decline in inflammation was
seen in women investing in reproduction (i.e. regu-
larly sexually active) but not in those who were not
investing in reproduction (i.e. sexually abstinent).
Interestingly, among ovulatory cycles, early-phase
inflammation in partnered women’s cycles was
higher than that of unpartnered women (but still
lower than that seen in the anovulatory cycles of ei-
ther partnered or unpartnered women). Exposure to
pathogens from the intimate partner [93], or vaginal
irritation due to sexual activity and/or exposure to
condoms [94], can prompt immune response
including mild inflammation; however, responding
with anovulation to this moderate rise in inflamma-
tion would prevent conception. The female repro-
ductive system may attenuate responsiveness to
inflammation under the conditions of partnership;
that is, sexual activity and/or sexual partnership may
tip the balance between reproduction and immunity
in favor of reproduction. This may occur via alter-
ations in hypothalamic receptor sensitivity for in-
flammatory cytokines [95], which would in turn
blunt the signal received by the HPG (hypothal-
amic-pituitary–gonadal) axis. Broadly, these
findings support the hypothesis that ovarian cycle
variation in inflammation contributes to coordin-
ation of the trade-off between reproduction and
immunity.
This Bolivian study population, alongside other
studies in less-industrialized nations and popula-
tions experiencing significant environmental stress
[54–57, 66, 67, 96, 97], offers a valuable counterpoint
to the extant clinical literature. The vast majority of
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Figure 4. Cardiovascular (CVD) risk category (according to AHA guidelines) differs by cycle phase (early cycle: before Day 14;
late cycle: after Day 14) and ovulation status
Mediating reproductive-immune investments Lorenz et al. | 317
D
ow
nloaded from
 https://academ
ic.oup.com
/em
ph/article-abstract/2015/1/304/1798160 by guest on 03 June 2020
research on CRP and female reproductive health has
been conducted in white women of middle to high
SES living in wealthier (industrialized/post-
industrialized) nations. Such limited representation
of human variation is problematic given the evi-
dence that women living in these wealthier societies
differ significantly in diet, lifestyle, and reproductive
history from those in poorer, less-industrialized and
agrarian societies and consequently, differ signifi-
cantly in the degree and chronicity of inflammation
[98]. The participants in our study experienced sig-
nificant physiologic stress from energetic demands
(chronically low calorie and/or nutrient intake, and a
lifestyle more physically demanding than typical of
post-industrialized populations), a cold and arid cli-
mate, and limited financial assets. In addition, des-
pite relatively higher exposure to pathogens,
Bolivians typically have a much lower exposure to
immunoactive medications (e.g. antibiotics) than
individuals living in wealthier nations [99–101].
Although such differences between poorer and
wealthier countries can be expected to have import-
ant consequences for immune function, it is note-
worthy that even within this Bolivian sample, the
poorest women exhibited significantly lower CRP
than the subsample of better-off women. Similarly,
in Ecuadorian lowland men and women, McDade et
al. [63] found relatively lower CRP among individuals
living in areas with high rates of infections compared
with US populations under low risk of infection (but
see also [57] for contrasting findings from a Bolivian
lowland population). Such differences may
have immunodevelopmental roots: for instance,
Philippine adults who had experienced higher levels
of microbial exposure in infancy [54] have lower
levels of CRP. Although our data are valuable for
being among the first to examine inflammation-
related anovulation in a non-industrialized popula-
tion, obviously they are by no means representative
of all non-industrialized populations. Examining the
diversity of the human species across habitats, cli-
mates and cultures will strengthen our models of
immune response and reproduction [25, 38].
Context within previous research
Published findings on variation in CRP across the
ovarian cycle of healthy women in Western popula-
tions are mixed, with reports that CRP peaks at mid-
cycle, nadirs at mid-cycle, rises across the cycle, or
does not vary systematically across the cycle [74–78].
This wide variety of findings may be due in part to
differences in inclusion and/or accounting for an-
ovulatory cycles. One study that compared ovulatory
and anovulatory cycles found differences in CRP at
the early and mid-cycle time-points but not late
cycle, with higher CRP in ovulatory than anovulatory
cycles [76]. Another study that controlled for differ-
ences in luteal phase P4 in their sample of ovulatory
and anovulatory cycles showed a U-shaped curve
with lowest CRP around ovulation [78]. Taken to-
gether with the present study, these findings suggest
that ovulatory and anovulatory cycles differ signifi-
cantly in patterns of CRP, a finding also supported by
studies of ovarian wave dynamics [43]. Of note, this
may also explain why reports about the association
of CRP with variations in ovarian hormones have
been so inconsistent, with some reports suggesting
that E2 or P4 is pro-inflammatory and others, anti-
inflammatory [74, 77, 78]. It is possible that ovula-
tion itself—a distinct phenomenon that is related to,
but not entirely covariant with, hormone concentra-
tions [81, 102]—is more pertinent to understanding
changes in CRP during the ovarian cycle than are
ovarian hormone concentrations per se. There is evi-
dence of such direct crosstalk between immune and
reproductive systems, with cytokines acting on
neural circuits that mediate sexual behavior, and po-
tentially, vice versa [103].
Other reports indicate that sexual partnership in-
fluences reproductive hormone profiles across the
menstrual cycle in healthy women, such that sexually
partnered women have lower testosterone but higher
mid-cycle estradiol and luteal phase progesterone
than unpartnered women [84, 104, 105]. These
studies frequently have been limited by lack of con-
sideration of ovulation or anovulation rates. However,
given the work showing higher rates of ovulation
among sexually partnered women [82–85], it is likely
there is a significant role for the social and sexual
environments as predictors of ovarian function,
and, by extension, immune function.
Several studies have found significant differences
between partnered and unpartnered women in
terms of endocrine function [104, 106–109], and,
among healthy individuals, immune function [49].
Compared with unpartnered women, partnered
women have higher estradiol but lower testosterone,
and higher luteal progesterone. Higher estradiol
early in the cycle (that is, in the absence of proges-
terone) is associated with higher markers of inflam-
mation such as interleukin-6 [110]; thus, partnered
women are likely to have higher levels of early-cycle
inflammation than unpartnered women.
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Analyses reported in previous studies of CRP
across the ovarian cycle routinely exclude data from
participants with CRP levels over 3 mg/l, as the AHA
and the Centers for Disease Control have defined
CRP values>3 mg/l as ‘pathological’ and not reflect-
ing healthy individuals. However, the ‘pathology’ in
this case is CVD [29] and not frank infection (during
which CRP levels are closer to 10–100 mg/l) [111].
Eliminating values over 3 mg/l restricts our under-
standing of CRP variation during the ovarian cycle by
disregarding the normal function of inflammation,
which is to increase dramatically but transiently in
response to infection or wound healing. In wealthier
populations, exposure to pathogens is typically
lower and elevated CRP thus more typically reflects
pathology; similarly, anovulation in wealthier popu-
lations is often associated with estrogen
dysregulation and thus has been characterized as a
pathological state [112].
However, our findings suggest that in populations
exposed to environmental stressors demanding an
immune response, anovulation may be adaptive.
Several studies have suggested that high pathogen
exposure early in life leads to higher adult immune
response to pathogens, but also lower chronic in-
flammation in adulthood [25, 63]. This in turn may
help balance reproductive and immune investments
because inflammation is, for these populations, a
signal of an acute state. In a large, well-conducted
trial in healthy US women, Gaskins et al. [78] found
that although 32% of women had elevated CRP
values during at least one point of their cycle, CRP
values were consistently high across multiple cycles
in only 2% of cases; in other words, high inflamma-
tion in one measurement within one cycle rarely pre-
dicted high inflammation in other measurements.
This pattern of CRP elevations as generally transient
further reflects the dynamic nature of inflammation,
and its responsiveness to changing conditions
within the body.
Clinical implications
The hypothesis that anovulation may be an adaptive,
flexible strategy deployed to regulate reproductive
fitness on a cycle-by-cycle basis vis-à-vis inflamma-
tion load suggests important clinical implications.
First, given CRP’s role as a marker of CVD and
other inflammation-related conditions, variations
in CRP across the ovarian cycle can confound clinical
interpretation. Recent studies have suggested that
failure to account for ovarian cycle variation in CRP
contributes to a 3-fold over-diagnosis of CVD risk in
healthy women [86]. We found that healthy women
with anovulatory cycles were significantly more likely
to be classified as moderate or high risk of CVD ac-
cording to the AHA-recommended classification
system if tested early in their cycle rather than late
cycle [32]. That is, if a women presents for evaluation
of her CVD risk during an anovulatory cycle, there is a
significant chance she will be differently classified
(and likely misclassified) if she presents early versus
late in her cycle. These findings suggest that in
women of reproductive age, single tests of CRP
may have limited prognostic value, and instead sup-
port tracking patients’ CRP over time or, at a min-
imum, scheduling a test at about the end of the
second week of the cycle, a time when our findings
suggest that CRP in healthy women is most likely to
be at a nadir in all cycles regardless of ovulation or
partnership status.
Second, the chronicity of inflammation may have
a greater impact on reproduction than does the de-
gree. That is, because acute inflammation appeared
to impact ovulation on a cycle-by-cycle basis, we
would expect that ongoing ovarian disruption would
be due to ongoing inflammation rather than high
inflammation per se. Moreover, anti-inflammatory
treatments (including diets and lifestyle changes)
are increasingly recommended as first-line interven-
tions for many diseases, including infertility and
polycystic ovarian syndrome (PCOS). For example,
Boots and Jungheim [113] argued that anti-
inflammatory behavioral treatments may improve
both pain and poor folliculogenesis in women with
PCOS. Our findings suggest that such treatments
would have the greatest impact on ovulation if ad-
ministered early in the current ovarian cycle. Indeed,
anti-inflammatory treatments administered in mid-
or late-cycle may have little effect on anovulation-
related infertility.
Strengths and limitations
Limitations of our study include a moderate sample
of participants (n = 61) (however, sample sizes in all
but one published study [78] were n 36). Because
hormone data were only available for every other day,
our maximum precision for determining timing of
ovulation was a range of 2 days.
As CRP is a non-specific marker of inflammation,
the precise cause of high CRP (infection, wound
healing, diet, stress, or some other factor) cannot
be ascertained. Similarly, we cannot know, based
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on this study alone, which of the many aspects of a
sexual partnership underlie the associations be-
tween reproduction and immune function reported
here. Future studies should further examine the
mechanisms that drive the observed interactions be-
tween partnership, hormones and inflammation.
It is also worth noting that selection bias for less
fecund women can occur in a cross-sectional study of
menstruating women in a natural fertility population
because the most fecund women are likely to be ei-
ther pregnant or lactating, and hence unavailable for
such a study [38, 114]. Although our sample has
demonstrated high fertility (median parity to date
was three births for the currently partnered women,
with each birth followed by a prolonged period of
lactation, during 8 years of partnership) [52, 81],
it is possible that our sample in this study is biased
in this manner and that the relationships among in-
flammation, ovulation and partner status that we
observed differ in some way between women of
higher and lower fecundity. To evaluate this possibil-
ity requires additional (e.g. longitudinal) research.
Whether our results apply to women outside the age
range of our sample also remains to be tested. This
was a sample of young women who were relatively early
in their childbearing years. Life-history theory suggests
that the threshold to reproductive investment is lower
in older women (particularly those without prior off-
spring) [25]. Thus, potentially, anovulation would not
be associated with inflammation in an older sample or
would be associated with higher inflammation levels
than were observed in our sample.
Strengths of our study include multiple consecu-
tive cycles for each woman, multiple CRP measure-
ments during the 2 weeks around mid-cycle,
determination of ovulation/anovulation based on
well-characterized hormonal profiles, good statis-
tical controls for individual differences in baseline
CRP and a novel population.
Conclusions
We identified a link between markers of inflamma-
tion and ovarian function, whereby ovulation was
associated with a mid-cycle decrease in inflamma-
tion while anovulation was associated with high in-
flammation early in the ovarian cycle. We also found
evidence for cycle-by-cycle specificity of inflamma-
tion patterns, such that inflammation in one cycle
did not influence ovulation in other cycles (and vice
versa). This study also demonstrates a need to con-
sider social factors such as sexual behaviors as
powerful signals that help coordinate immune activ-
ity, which in turn may regulate reproductive invest-
ment via permitting or disrupting ovulation.
Although further work is needed to elucidate the
mechanisms underlying these effects, our findings
suggest an important role for sociosexual behavior
in balancing reproductive and immune priorities.
Harnessing such effects may prove to be trans-
formative in preventing sexually transmitted dis-
eases and promoting women’s sexual health.
Moreover, the findings speak directly to the clinical
interpretation of CRP as a biomarker of CVD risk, as
there is significant variation in CRP (and thus, the
apparent associated risk prognosis) within the same
(healthy) individual during the course of the ovarian
cycle, and with partnership status in ovulatory
cycles. The translational import of our findings sug-
gests that clinical interpretation of inflammation
biomarkers such as CRP without including consid-
eration of reproductive variables (ovarian cycle
phase, sexual activity status) is at best incomplete
and at worst inaccurate. This is the first such study in
a non-industrialized population, and contributes to
a growing literature on life history and the ecology of
women’s immune function. As such, this and future
studies will provide a foundation for understanding
how trade-offs between reproduction and immunity
play out in women worldwide.
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